VHPB TECHNICAL MEETING
+++Online+++  
Viral hepatitis treatment as prevention (TAP)

Part I: 15 October 2020 – 16H30 until 19H30  
Part II: 22 October 2020 – 16H30 until 19H30  

Draft MEETING agenda
Meeting practical's

• Due to time constraints the presentations were not pre-recorded

• All speakers will present 15 minutes

• To facilitate the discussion
  • Switch on your camera

• Mute yourself when you don’t speak
Meeting practicals

• Introduce yourself shortly when you intervene

• If you would like to speak up, you can either:
  • Physically raise your hand so it is visible on screen.
  • Use the ‘raise your hand’ button
    » Open participants list
    » In right column “raise hand”
• Viral Hepatitis Prevention Board
• Viral hepatitis expert board – for more than 28 years

• Mission statement

The objective of VHPB is to contribute to the control and prevention of viral hepatitides.

> All activities are in line with viral hepatitis elimination goals defined by WHO Global strategy

> Focus audiences are, in first instance, opinion leaders, policymakers, public health and health care professionals

• More info www.vhpb.org
Agenda

• Part I: Treatment As Prevention (TAP) hepatitis C in risk groups

• Part II: Treatment as to prevent perinatal mother to child transmission (MTCT) of hepatitis B – Liver disease progression

Next week: 22 October 2020
Meeting Objectives

- Viral hepatitis treatment as prevention (TAP) to prevent MTCT
  - Give an overview of the scientific evidence to use treatment during pregnancy to avoid perinatal transmission of hepatitis B
  - Discuss the new perinatal WHO recommendations on hepatitis B Prevention of mother to child transmission of hepatitis B focusing on the use of treatment during pregnancy
  - Discuss the possible impact of treatment as prevention of perinatal transmission on the triple elimination goals.
Meeting Objectives

- Viral hepatitis treatment as prevention (TAP) to Disease progression
  - Review scientific evidence for treatment of all hepatitis B positives to prevent disease progression,
  - Discuss if treatment to prevent disease progression could be a public health recommendation
Agenda Treatment As Prevention (TAP) hepatitis B MTCT

• **Session 2.1**: Treatment as to prevent perinatal mother to child transmission (MTCT) of hepatitis B
  - 15 min presentation pre-recorded/ live

• **Discussion session** (20 min)
  1. Are the new WHO recommendations on HBV prevention of perinatal transmission, including TAP and added value to reach the hepatitis elimination goals?
  2. In low endemic countries (Europe) should we focus on Screening and TAP in pregnant women or on Birth dose vaccination or both?
**Agenda** Treatment As Prevention (TAP) hepatitis B Liver disease progression

- **Session 2.2 : Treatment to prevent liver disease progression**
  - 15 min presentation pre-recorded/ live

- **Discussion session (20 min)**
  1. Is there enough scientific evidence to recommend treatment to prevent liver disease progression in the context of public health
  2. Is treatment for all patients who tested positive for Hepatitis B feasible (resources)
Tour de table
Introduction of participants

• Introduce your self shortly